Intelligence · Patents
Patents expiring in 2033
Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.
- Patents
- 1,330
Quick answer
1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8541182
Biological marker for inflammation
granted -
US 8541371
Treatment of conditions related to cecal ligation shock
granted -
US 8541403
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
granted -
US 8541231
Elimination of N-glycolylneuraminic acid from animal products for human use
granted -
US 8546364
Stabilized steroid composition and method for its preparation
granted -
US 8545813
Pre-templated macromolecular architectures with multiple Gd(III) complexes and methods of use as MRI contrast agents
granted -
US 8545885
Stable laquinimod preparations
granted -
US 8546348
Upregulation of opioid receptors for management
granted -
US 8546371
Nanoparticle formulated glycolipid antigens for immunotherapy
granted -
US 8546433
Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
granted -
US 8545225
Redox-curing type composition
granted -
US 8545847
Human antibodies to the human glucagon receptor and methods of use thereof
granted -
US 8545927
Lactoferrin-based biomaterials for tissue regeneration and drug delivery
granted -
US 8546091
AKT phosphorylation at Ser473 as an indicator for taxane-based chemotherapy
granted -
US 8545888
Tendon stem cells
granted -
US 8546322
Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof
granted -
US 8546331
Modulation of pathogenic CD14+/CD16+ monocytes
granted -
US 8546143
Compositions and methods for inhibiting expression of a target gene
granted -
US 8546376
Pharmaceutical compounds
granted -
US 8546398
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
granted -
US 8546493
Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
granted -
US 8546414
Ion channel modulators and methods of use
granted -
US 8546524
Smoothened polypeptides and methods of use
granted -
US 8546554
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
granted -
US 8546612
Phenyl-N-acyl derivatives of amines and amino acids, a process for the preparation thereof, a pharmaceutical composition and use thereof
granted -
US 8548557
Medical electrodes
granted -
US 2013261160
METHOD OF PREPARATION OF METAXALONE
granted -
US 8551966
Chemical compounds
granted -
US 8551945
Methods and compositions for treating neuropathies
granted -
US 8551726
Method of modulating HSF-1
granted -
US 8551536
Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes
granted -
US 8551467
Replenishment and enrichment of ocular surface lubrication
granted -
US 8551448
Rotanone analogs: method of preparation and use
granted -
US 8552198
Benzimidazole compound crystal
granted -
US 8552147
Peptides and compositions for prevention of cell adhesion and methods of using same
granted -
US 8552167
Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing
granted -
US 8552067
Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses therefor
granted -
US 8552150
MART-1 T cell receptors
granted -
US 8552034
Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
granted -
US 8552018
Substituted tricyclic compounds as protein kinase inhibitors
granted -
US 8551936
Defensin-antigen fusion proteins
granted -
US 8551526
Preparation of drug particles using evaporation precipitation into aqueous solutions
granted -
US 8551965
Anti-viral pyrimidine nucleoside analogues
granted -
US 8551964
Hsp90 inhibitors with modified toxicity
granted -
US 8552088
Cement for dental applications
granted -
US 8552037
Tricyclic compound and pharmaceutical use thereof
granted -
US 8552006
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8551997
Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
granted
Frequently asked questions
How many pharma patents expire in 2033?
1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.